乌龙制药 URGN 深 沪
已收盘 05-08 16:00:00 美东时间
29.40
+2.810
+10.57%
华盛通- 最 高30.45
- 今 开26.95
- 成交量 169.67万股
- 最 低 26.95
- 昨 收 26.59
- 总市值 14.32亿
- 52周最高 30.45
- 市盈率 静 --
- 换手率 3.48%
- 52周最低 3.42
- 委 比 0.62%
- 总股本 4872.17万
- 历史最高 69.568
- 量 比 1.32
- 振 幅 13.16%
- 历史最低 3.42
- 每 手 1
- 风险率 5.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $34 to $40.
05-07 20:57
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. will participate in three investor conferences in May 2026: the Bank of America Health Care Conference on May 13th in Las Vegas, the HC Wainwright 4th Annual BioConnect Investor Conference on May 19th in New York, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26th virtually. Webcasts will be available on UroGen’s Investor Relations website, with replays accessible for approximately 90 days.
05-07 12:00
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
UroGen Pharma (NASDAQ:URGN) reported first-quarter financial results on Wednesd...
05-06 23:12
UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 48.91 percent increase over losses of $(0.92) per share from the
05-06 20:01
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Pharma reported strong Q1 2026 financial results, with ZUSDURI generating $29.2 million in revenue, up 109% Q/Q, and JELMYTO reaching $21.7 million, up 7% Y/Y. The company advanced its pipeline, with UGN-103 on track for NDA submission in H2 2026, and UGN-501 nearing IND submission. UroGen highlighted its expanding commercial momentum, growing clinical confidence in ZUSDURI, and plans to host a KOL panel at the AUA meeting. The company end...
05-06 12:00
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma announced the publication of long-term results from the Phase 3 ENVISION trial for ZUSDURI, showing a 72.2% probability of remaining event-free at 24 months after achieving complete response (CR). The CR rate at three months was 79.6%, with a median follow-up of 23.7 months. ZUSDURI, approved for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), offers a six-week induction treatment wit...
03-30 12:00
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
A survey of more than 1,100 bladder cancer patients reveals that nearly 80% experience fear of recurrence, rising to over 90% among those under 50. Many patients undergo five or more cystoscopies, with some enduring more than 15 procedures. UroGen Pharma and BCAN highlight the chronic nature of bladder cancer, emphasizing the need for treatment discussions that address long-term quality of life and emotional burden. The report underscores the cum...
03-13 12:00
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. granted 11 new employees inducement restricted stock units (RSUs) to support the commercialization of JELMYTO® and ZUSDUR™ and advance its pipeline. Up to 51,200 shares are issuable upon vesting over three years, contingent on continued employment.
03-06 21:10
